Veradermics Reports Positive Phase 2 Results for Oral Hair Loss Drug VDPHL01
Veradermics reported positive topline results from its open-label Phase 2 trial evaluating oral drug VDPHL01 in women with mild-to-moderate pattern hair loss. The treatment showed consistent hair growth, early onset of activity within two months, and was well tolerated.
Topics: female pattern hair loss hair loss drug Phase 2 trial results